by Vandana Singh | Oct 9, 2026 | General
Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study. The trial evaluated the effectiveness of administering the company’s iDose TR therapy alongside...
by Akanksha Bakshi | Oct 9, 2026 | General
Gorilla Technology Group Inc. (NASDAQ:GRRR), an AI technology provider, is trading lower on Friday. The company outlined plans to enter the U.S. AI infrastructure market through its proposed first data center acquisition. • Gorilla Tech stock is showing notable...
by Evette Mitkov | Oct 9, 2026 | General
Clover Health Investments Corp (NASDAQ:CLOV) shares are jumping Friday. The Centers for Medicare & Medicaid Services awarded the company’s Medicare Advantage plans high 2027 Star ratings. Clover Health Investments shares are climbing with conviction. What’s...
by Benzinga Insights | Oct 9, 2026 | General
Novanta (NASDAQ:NOVT) has outperformed the market over the past 15 years by 7.15% on an annualized basis producing an average annual return of 20.4%. Currently, Novanta has a market capitalization of $4.86 billion. Buying $100 In NOVT: If an investor had bought $100...
by Vandana Singh | Oct 9, 2026 | General
The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to market Weltruza, a once-monthly subcutaneous injectable for adult patients with schizophrenia. • Teva Pharmaceutical stock is challenging resistance....
Recent Comments